Specialists and generalists in the expanding outsourcing market
In this Issue:
From preclinical development to market approval, pharma companies increasingly rely on the competencies of customized biomanufacturing and preclinical & clinical research services: from DoE, QbD over process development to customized and even continuous USP, DSP and fi lling vials. However, with novel formats for biologics such as ADCs, glycooptimised of multifunctional antibodies or TCRs and CAR-Ts providing the most economic cell lines, media, or up- and downstream processes become more complex. The same is true for new formulations, trial formats (adaptive trails) and statistics approaches or ITC-based recruiting.
You want to be part of European Biotechnology?